New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections
New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections.
A beta-lactam (cephalexin, etc) USED to cover both purulent skin infections due to staph and cellulitis due to strep.
But now most staph skin infections are due to community-acquired methicillin-resistant Staph aureus (CA-MRSA) and therefore are resistant to beta-lactams.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote